Effective multiple oral administration of reverse genetics engineered infectious bursal disease virus in mice in the presence of neutralizing antibodies

ConclusionsRepeat oral administration of R903/78 was successful despite the presence of neutralizing antibodies. Single oral and IV administration indicated that IBDV does not replicate in mammalian liver alleviating some safety related concerns. These data supports the development of an orally delivered anti‐HBV/HCV viral agent for human use. This article is protected by copyright. All rights reserved.

Source: The Journal of Gene Medicine - January 1, 2015 Category: Genetics & Stem Cells Authors: Ákos Hornyák, Kai S. Lipinski, Tamás Bakonyi, Petra Forgách, Ernő Horváth, Attila Farsang, Susan J. Hedley, Vilmos Palya, Tibor Bakács, Imre Kovesdi Tags: Research Article Source Type: research